In Plain English—COVID-19, the vaccines, and melanoma: What do melanoma patients and their families need to know?
By Kim Margolin, M.D. Coronavirus is novel (new), and the vaccines are even newer, so little melanoma-specific information is…
02/23/2021
In Plain English—COVID-19, the vaccines, and melanoma: What do melanoma patients and their families need to know?
By Kim Margolin, M.D. Coronavirus is novel (new), and the vaccines are even newer, so little melanoma-specific information is…
|
01/10/2021
In Plain English—Intratumoral Injection: Boosting the immune response against metastatic melanoma by the direct injection of immunotherapy into tumor masses
By Kim Margolin, M.D. Using the patient’s own immune system to combat melanoma is a powerful tool for patients…
|
11/12/2020
In Plain English—Neo-Adjuvant Therapy for Palpable/Resectable Stage III Melanoma
By Kim Margolin, M.D. In this chapter of “In Plain English,” we will describe the concept of neo-adjuvant therapy. Certain terms…
|
09/29/2020
In Plain English: What is a “Triplet,” and Why Does it Matter in Melanoma?
By Kim Margolin, M.D. A “triplet” is the casual term to describe the combination of three drugs to treat cancer.…
|
01/23/2020
In Plain English: The Role of Dermatopathologists in Diagnosing Melanoma Patients
Let’s start at the moment you are getting your skin checked at your dermatologist’s office. If everything looks normal,…
|
11/14/2019
In Plain English: What’s New in Stage II?
There is news to report in the world of Stage II melanoma, but first, let’s review the basics of…
|
06/11/2019
In Plain English: Options for Stage III Melanoma
Our new guide, Options for Stage III Melanoma: Making the Decision That’s Right for You, is written for patients, families,…
|
09/05/2018
In Plain English: The Keynote 716 Clinical Trial
As of this writing, there are 477 clinical trials in melanoma on ClinicalTrial.gov that are actively recruiting patients—and another 65…
|
03/07/2018
In Plain English… The Excitement Surrounding Opdivo
So the FDA granted regular approval to nivolumab (OPDIVO, Bristol-Myers Squibb Company) for the adjuvant treatment of patients with melanoma…
|
Recent Posts
Apr. 16, 2024
Navigating the Journey Together – Conversations with Melanoma Caregivers
Apr. 12, 2024
May is Brain Tumor Awareness Month
Apr. 11, 2024
President’s Letter | April 2024
Apr. 11, 2024
Celebrating a Milestone: 20 Years of the Dallas Steps Against Melanoma Walk
Apr. 11, 2024